4 Jan 2024 • Opting for reduced-dose alteplase (50 mg) in hospitalized pulmonary embolism patients showed comparable outcomes to full-dose (100 mg) but with lower hemorrhagic risks.

The reduced-dose group had fewer hemorrhagic complications (13% vs. 24.5%), particularly major extracranial hemorrhages (1.1% vs. 6.1%).

Crucially, there were no significant differences in mortality, ICU/hospital stay lengths, or readmission rates.

Source: Critical Care Medicine | Read full story